New HIV prevention drug expected to be approved in China in 2027. The effectiveness of the new HIV prevention drug exceeds 99.9%.

At the 8th China International Import Expo, Jin Fangqian, Vice President and General Manager of Gilead Sciences in China, revealed in an interview with media such as Times Finance that the company's long-acting HIV pre-exposure prophylaxis drug Lenacapavir will be submitted for market approval in China in early next year, with approval and market availability expected in 2027 in China. Lenacapavir is the world's first long-acting HIV capsid inhibitor that only needs to be administered twice a year. Previous clinical trial data has shown that in a global Phase III clinical study on the use of Lenacapavir for HIV pre-exposure prophylaxis, its effectiveness in preventing HIV exceeds 99.9%.